These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 2537417)

  • 1. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.
    Nagaya H; Satoh H; Kubo K; Maki Y
    J Pharmacol Exp Ther; 1989 Feb; 248(2):799-805. PubMed ID: 2537417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
    Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
    J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.
    Nagaya H; Satoh H; Maki Y
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1289-95. PubMed ID: 2156997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the enantiomers of lansoprazole (AG-1749) on (H+ + K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells.
    Nagaya H; Inatomi N; Nohara A; Satoh H
    Biochem Pharmacol; 1991 Oct; 42(10):1875-8. PubMed ID: 1660270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
    Kinoshita M; Saito N; Noto T; Tamaki H
    J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
    Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
    Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms.
    Fryklund J; Wallmark B
    J Pharmacol Exp Ther; 1986 Jan; 236(1):248-53. PubMed ID: 3001289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omeprazole, a specific inhibitor of gastric (H+-K+)-ATPase, is a H+-activated oxidizing agent of sulfhydryl groups.
    Im WB; Sih JC; Blakeman DP; McGrath JP
    J Biol Chem; 1985 Apr; 260(8):4591-7. PubMed ID: 2985559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Discovery and development of the proton pump inhibitor].
    Igata H; Okabe S
    Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of gastric proton pump inhibition by calcium channel antagonists.
    Nandi J; King RL; Kaplan DS; Levine RA
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1102-7. PubMed ID: 2156990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oleic acid as an inhibitor of gastric H+, K(+)-ATPase.
    Murakami S; Muramatsu M; Otomo S
    Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):337-50. PubMed ID: 1646470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
    Wallmark B; Lorentzon P; Larsson H
    Scand J Gastroenterol Suppl; 1985; 108():37-51. PubMed ID: 2988109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
    Nishioka K; Nagao T; Urushidani T
    Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.
    Smolka AJ; Goldenring JR; Gupta S; Hammond CE
    BMC Gastroenterol; 2004 Feb; 4():4. PubMed ID: 15028114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possible mechanisms for (H+ + K+)-ATPase inhibition by proton pump inhibitors, omeprazole, lansoprazole and SCH 28080].
    Nagaya H; Satoh H
    Nihon Rinsho; 1992 Jan; 50(1):26-32. PubMed ID: 1311786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of gastric H+, K+-ATPase by 3-amino-5-methyl-2-(2-methyl-3-thienyl)imidazo[1,2-a]thieno[3,2-c]pyrid ine, SPI-447.
    Ushiro T; Tsukimi Y; Tanaka H
    Jpn J Pharmacol; 1997 Nov; 75(3):303-6. PubMed ID: 9434264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of gastric K+/H+-ATPase by acid-activated 2-((2-pyridylmethyl)sulphinyl)benzimidazole products.
    Beil W; Hannemann H; Mädge S; Sewing KF
    Eur J Pharmacol; 1987 Jan; 133(1):37-45. PubMed ID: 3030771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gastric H+,K+-ATPase: the site of action of omeprazole.
    Sachs G; Wallmark B
    Scand J Gastroenterol Suppl; 1989; 166():3-11. PubMed ID: 2557669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.
    Fellenius E; Berglindh T; Sachs G; Olbe L; Elander B; Sjöstrand SE; Wallmark B
    Nature; 1981 Mar; 290(5802):159-61. PubMed ID: 6259537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.